Published in Drug Week, June 9th, 2006
According to recent research from Canada, "Efalizumab targets T cell-mediated steps important in psoriasis immunopathogenesis. We sought to evaluate the efficacy and safety of efalizumab retreatment in patients with moderate-to-severe plaque psoriasis. In this open-label, phase III study, 365 patients who received efalizumab therapy during an earlier clinical trial were retreated with 12 weeks of subcutaneous efalizumab (1 mg/kg/wk) 35 days or more after their last dose of efalizumab."
"After 12 weeks of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.